Everyone

Michael Pehl, MSc

Michael Pehl, MSc

CEO

+25 years of global pharmaceutical & biotech leadership experience. Former CEO of GEMoaB, CEO of Immunomedics, and President of Hematology & Oncology at Celgene

John Doe, PhD

John Doe, PhD

CSO

Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

Carmel M. Lynch, PhD

Carmel M. Lynch, PhD

CDO

+25 years of experience in biotechnology, spanning from discovery research to clinical development, with an emphasis in translational medicine. +15 years specializing in ADCs; led Nonclinical and Clinical Pharmacology development of Adcetris(tm) ADC at SeaGen from pre-IND to approval in 2011

Pernille Hemmingsen, PhD

Pernille Hemmingsen, PhD

CTO

+20 years experience in the pharmaceutical industry. Former VP, Global Product Development and Supply at Savara ApS. 5 years at Genmab, leading ADC CMC and manufacturing, from non-clinical to phase II development

Christoffer Nilelsen, PhD

Christoffer Nilelsen, PhD

COO & Co-Founder

Established the scientific project on utilization of receptors for targeted drug delivery by ADCs at The Finsen Laboratory, which became Adcendo. Molecular Biologist by training, founding CTO of Adcendo from 2017-2021